What it's for (Indications)
- Betamethasone dipropionate and clotrimazole topical cream is indicated for the topical treatment of inflammatory dermatoses where a potent corticosteroid is appropriate and a fungal infection caused by susceptible organisms is present.
- This includes conditions such as tinea pedis, tinea cruris, and tinea corporis, when accompanied by significant inflammatory symptoms like itching, redness, and swelling.
- It is particularly useful when the inflammatory component is pronounced, necessitating the anti-inflammatory action of a corticosteroid in addition to the antifungal activity.
- The combination therapy targets both the fungal pathogen and the host inflammatory response, aiming to provide more rapid symptomatic relief compared to antifungal therapy alone.
- Prior to initiation of therapy, a confirmed diagnosis of dermatophyte infection should be established, and the medication should not be used empirically for non-fungal inflammatory conditions due to the corticosteroid component.
- It is not indicated for primary treatment of fungal infections without significant inflammatory components, nor for diaper dermatitis where corticosteroids are generally contraindicated.
- The duration of therapy should be limited to minimize the risk of corticosteroid-related adverse effects.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | This medication should be applied as a thin film to the affected skin areas once or twice daily, depending on the severity of the condition and clinical response, as directed by a healthcare professional. For optimal absorption and efficacy, the affected skin should be clean and dry before application. The duration of treatment should generally not exceed two weeks for tinea cruris and tinea corporis, and four weeks for tinea pedis. Prolonged use beyond these recommended durations is not advised due to the potential for systemic absorption of the corticosteroid and associated adverse effects. Occlusive dressings should not be used over the treated area unless specifically instructed by a physician, as occlusion significantly increases the systemic absorption of betamethasone. Use in pediatric patients should be approached with extreme caution, and typically, this combination is not recommended for children under 12 years of age for prolonged periods or on large body surface areas, owing to their increased susceptibility to systemic corticosteroid effects. The total dosage applied should not exceed 45 grams per week. Patients should be instructed on proper application techniques and the importance of adhering to the prescribed duration of therapy. |
Safety & Warnings
Common Side Effects
- Topical betamethasone dipropionate and clotrimazole can cause a range of adverse effects, primarily local, but systemic effects are possible, especially with prolonged use, application to large surface areas, or under occlusion.
- Common local side effects attributed to the corticosteroid component include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
- Local side effects specifically associated with clotrimazole include erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general skin irritation.
- Systemic adverse effects, though less common with topical use, can occur due to corticosteroid absorption and include suppression of the hypothalamic-pituitary-adrenal (HPA) axis, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Pediatric patients are particularly susceptible to systemic effects.
- If signs of local irritation, sensitization, or superinfection develop, treatment should be discontinued, and appropriate therapy instituted.
- Any persistent or worsening adverse reactions should prompt immediate medical evaluation.
Serious Warnings
- Black Box Warning: Serious Warnings: Although no formal FDA Black Box Warning exists for topical betamethasone dipropionate and clotrimazole, significant precautions are warranted due to the potential for serious adverse effects, particularly related to the corticosteroid component. Systemic absorption of betamethasone can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, which may result in glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also occur. The risk of these systemic effects is heightened with prolonged use, application to large body surface areas, use under occlusive dressings, and in pediatric patients. Pediatric patients are especially vulnerable to systemic toxicity due to their larger skin surface area-to-body weight ratio. Therefore, this medication should be used with extreme caution in children, typically not for prolonged periods, and only when clearly indicated. Furthermore, local adverse reactions, such as skin atrophy, striae, telangiectasias, and secondary infections, are possible with prolonged or inappropriate use of corticosteroids. Healthcare providers must carefully weigh the benefits against these serious risks, prescribe the smallest effective amount for the shortest duration, and monitor patients for signs of systemic and local adverse effects.
- Topical corticosteroids, including betamethasone, can be absorbed systemically, potentially causing reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
- Pediatric patients are at greater risk of HPA axis suppression and Cushing's syndrome due to a larger skin surface area to body weight ratio.
- Treatment should be limited to the minimum effective duration to control symptoms.
- Prolonged use, application to large surface areas, or use under occlusive dressings increases the risk of systemic effects.
- The medication is not for ophthalmic use; contact with eyes should be avoided.
- Patients should be advised to report any visual disturbances, as cataracts and glaucoma have been reported with systemic and, rarely, topical corticosteroid use.
- If local irritation or sensitization develops with the use of this medication, treatment should be discontinued, and appropriate therapy should be instituted.
- Betamethasone dipropionate and clotrimazole topical should not be used in the treatment of acne vulgaris, rosacea, perioral dermatitis, or skin manifestations of tuberculosis or viral infections (e.
- g.
- , herpes simplex, varicella).
- This medication is not recommended for diaper dermatitis.
- Use in pregnancy and lactation should be undertaken only if the potential benefit justifies the potential risk to the fetus or infant.
How it Works (Mechanism of Action)
The therapeutic action of this combination cream results from the distinct mechanisms of its two active components. Betamethasone dipropionate is a synthetic, high-potency corticosteroid that exerts its effects primarily through its anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins control the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid, from membrane phospholipids. This ultimately reduces the inflammatory cascade in the skin. Clotrimazole is an azole antifungal agent that acts by inhibiting the biosynthesis of ergosterol, a critical component of fungal cell membranes. By binding to cytochrome P-450 enzymes, clotrimazole impedes the conversion of lanosterol to ergosterol. The resulting depletion of ergosterol and accumulation of other sterols in the fungal membrane leads to structural and functional damage, increasing membrane permeability, causing leakage of essential intracellular components, and ultimately leading to fungal cell lysis and death. Together, these two agents provide comprehensive treatment for inflammatory fungal skin infections by targeting both the pathogen and the host's inflammatory response.